Presidio Pharmaceuticals Adds $27M
San Francisco-based Presidio Pharmaceuticals said Thursday afternoon that it has raised another $27M for the firm. The company, which is focused on developing treatments for viral infections, including HIV-1 and HCV, said the round included New Leaf Venture Partners, Panorama Capital, Baker Brothers Investments, Ventures West Capital, Bay City Capital, Nexus Medical Partners and Sagamore BioVentures. The firm said the funding woul go towards advancing its HCV clinical candidate through clinical studies. Dr. Srinivas Akkaraju of New Leaf will join the board with the funding. The round brings the company's total raised to $54.5M.
posted on Thursday, July 9, 2009 (Link to more information)
Related companies:
Presidio Bay Ventures
Related stories:
> Presidio Pharmaceuticals Gets $26M
> Presidio Reinsurance Lands $50M In Equity From FTVentures
> Arriva Pharmaceuticals Adds $6M
> Karmasphere Digs Up $6M
> APT Pharmaceuticals Adds On $22M
silicontap.com Home